Berkeley Homes has announced plans to create the UK's tallest apartment block situated near London's financial district.

The construction of the residential tower would represent the company's first development on the Isle of Dogs and will continue the development work going on in the Canary Wharf area. The South Quay Plaza area will be home to a new mixed-use residential-led scheme to carry on the tradition of building projects which were originally laid out during Margaret Thatcher's tenure as prime minister.

Residents around Canary Wharf will be given the opportunity to the see the updated plans for the area as Berkeley Homes prepares to lodge a planning application to Tower Hamlets Council later in the year. People will be able to view the scheme at Lanterns Theatre Studio, Unit D of the Great East Enterprise at 3 Millharbour on Friday (July 19th) between 14:00 BST and 20:00 BST as well as on Saturday (July 20th) between 10:00 BST and 14:00 BST.

Berkeley Homes explained that the development will consist of an 80-storey main tower and two other 35-floor and six-floor buildings. The 250m structure would become the tallest building of its kind within the UK and dwarf One Canada Square which is currently Canary Wharf's tallest tower at 245m.

It will include around 1,150 luxury flats as well as 40,000 sq ft of retail space and 20,000 sq ft of offices. The building represents an opportunity for residents and businesses to take up location in one of the most sought-after places in London.

Harry Lewis of Berkeley Homes said: “At the first exhibition, residents were particularly keen to see improvements made to the public realm and pedestrian permeability. As a result we will be providing over 60 per cent of the site area as public realm, reactivating the waterfront and providing fantastic spaces for the local community to enjoy.”

Demolition and construction is expected to begin before the end of 2014 with the lower rise buildings beginning in 2017.

Contact us for a security fencing quote.ADNFCR-3337-ID-801614387-ADNFCR